GlobeNewswire by notified

AGC Biologics Named Manufacturing Company of the year by American Business Awards

Share

Global CDMO honored for Growth in Mammalian, Microbial and Cell and Gene Manufacturing capabilities at Seattle, Boulder and Longmont sites

SEATTLE, June 29, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it was named Company of the Year in the “Large - Manufacturing” category in the 20th Annual American Business Awards®. 

The American Business Awards are the U.S.A.’s premier business awards program. Nicknamed the Stevies for the Greek word meaning “crowned,” the awards were presented to winners at a gala ceremony at the Marriott Marquis Hotel in New York on Monday, June 13. More than 230 professionals worldwide participated in the judging process to select this year’s American Business Award winners. 

AGC Biologics has a global pharmaceutical manufacturing network with seven sites across three continents. Over the last two years, the company has expanded its capabilities and reach within the U.S. and now boasts strong campuses in Seattle, Boulder, Col., and Longmont, Col. Through these investments, AGC Biologics is establishing a reputation as one of the fastest-growing and innovative companies within the life science field.  

The global CDMO added more microbial and mammalian manufacturing lines to its Seattle site, increasing production efficiency. The expansion project eliminated bottlenecking and strengthened services for customers seeking support during the pre-clinical, clinical, and commercial phases of drug production; it also included the addition of a new 500-liter mammalian cell bioreactor to expand manufacturing capacity. The advancements at the Seattle site coincided with AGC Biologics securing more customers at the campus. For example, in 2020, the Seattle site was chosen by Novavax Inc. to produce materials for the company’s COVID-19 vaccine. The campus was also chosen to manufacture materials for a late-stage project for China-based I-MAB Biopharma. 

After acquiring and developing manufacturing sites in Boulder and Longmont over the last two years, AGC Biologics is now one of the largest biotech companies in Colorado. The Boulder facility offers one of the biggest mammalian-drug manufacturing lines in the U.S. and houses two 20,000-liter stainless steel cell bioreactors.  

The Longmont campus is the newest manufacturing site in the company’s global network and serves as AGC Biologics’ North American hub for cell and gene therapy manufacturing. The 622,000-square-foot facility offers cell therapy and viral vector development and manufacturing capabilities. 

At each of its seven global sites, AGC Biologics offers immediate and significant manufacturing capacity for small startup developers and large pharmaceutical companies bringing new biologics products and advanced therapies to market. 

To learn more about AGC Biologics’ global facilities and capabilities, visit https://www.agcbio.com/.  

About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

About the Stevie Awards
Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Ensurge Micropower ASA - Grant of Incentive Subscription Rights24.4.2024 23:30:00 CEST | Press release

The Board of Directors of Ensurge Micropower ASA (the "Company") resolved on 24 April 2024 to issue a total of 202,200 incentive subscription rights to employees in the Ensurge group. The grants were made under the Company's 2023 incentive subscription rights plan, as resolved at the Annual General Meeting on 24 May 2023, and amended on the Extraordinary General Meeting held on 10 November 2023. The exercise price of the subscription rights is calculated to NOK 1.2640 per share. The subscription rights expire on 24 May 2028. The subscription rights follow the terms and conditions of the 2023 subscription rights incentive plan. Following the grant there are 46,057,881 incentive subscription rights issued and outstanding in the Company. For more information, please contact: Lars Eikeland, Chief Executive Officer E- mail: lars.eikeland@ensurge.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Bombardier Unveils Bold New Brand Identity Worldwide as Company Soars Toward an Ambitious Future24.4.2024 23:12:07 CEST | Press release

A new logo celebrates the company’s successful shift toward pure-play business aviation. The symbol itself, the Bombardier Mach, features the silhouette of an aircraft breaking the sound barrier, while the strokes of wind over a wing reference the company’s heritageThe employee value proposition “where heart meets mastery” focuses on Bombardier’s talented people, celebrating the workforce’s renowned passion, its incredible craftsmanship and profound technological expertise MONTRÉAL, April 24, 2024 (GLOBE NEWSWIRE) -- Bombardier, the worldwide leader in business aviation, today unveiled a new brand identity anchored by the evolution of the company’s logo. As Bombardier successfully moves forward as a company with a sole focus on designing, building and servicing the world’s best business jets, the new brand identity will reinforce and propel the company’s unique approach to its customers and stakeholders—putting people at the centre and instilling a one-of-a-kind sense of family. Bombar

Vistin Pharma ASA: Annual Report 202324.4.2024 23:10:00 CEST | Press release

Oslo, Norway, 24 April 2024 Please find attached the Annual Report for 2023 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full year results presented on 16 February 2024. The annual report for 2024 will also be made available on www.vistin.com. ***** For further information, please contact: Alexander Karlsen CFO +47 97 05 36 21 Alexander.karlsen@vistin.com Attachments 2023 Annual Report Vistin Pharma ASAVistinpharmaasa-2023-12-31-en

Nokia Corporation: Repurchase of own shares on 24.04.202424.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 24 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 24.04.2024 Espoo, Finland – On 24 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL392,1193.43CEUX--BATE--AQEU--TQEX--Total392,1193.43 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Sveitarfélagið Árborg – Ársreikningur 202324.4.2024 20:40:35 CEST | Press release

Ársreikningur Sveitarfélagsins Árborgar fyrir árið 2023 var lagður fram í bæjarráði og til fyrri umræðu á fundi bæjarstjórnar í dag miðvikudaginn 24.04.2024. Rekstrarniðurstaða Sveitarfélagsins Árborg samkvæmt samanteknum rekstrarreikningi A og B hluta var neikvæð um 1.269 millj.kr. en samkvæmt samþykktri fjárhagsáætlun fyrir árið 2023 var gert ráð fyrir 1.855 mill.kr. neikvæðri rekstrarniðurstöðu. Uppfærð fjárhagsáætlun ársins 2023 gerði ráð fyrir 1.693 millj.kr. neikvæðri niðurstöðu. Tekjur ársins af A og B hluta námu alls 17.951 millj.kr., launakostnaður 9.686 millj.kr., hækkun lífeyrisskuldbindinga nam 658 millj.kr.. Annar rekstrarkostnaður var 5.622 millj.kr. og nemur framlegð því 1.984 millj.kr. Afskriftir voru 951 millj.kr.. Fjármunatekjur, fjármagnsgjöld og tekjuskattur námu 2.302 millj.kr. og var rekstrarniðurstaða ársins því neikvæð um 1.269 millj.kr. Veltufé frá rekstri var 1.713 millj.kr. eða 9,5% af heildartekjum A og B hluta. Skuldahlutfall hefur lækkað á árinu 2023 og er

HiddenA line styled icon from Orion Icon Library.Eye